If you have been reading about somatotroph and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-12-29. Where a claim depends on a specific study, the study is described rather than over-claimed.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
Premature menopause Gonadal dysgenesis, Turner syndrome, Klinefelter syndrome Castration Swyer syndrome Polyendocrine metabolic ovarian syndrome Certain forms of congenital adrenal hyperplasia Testicular failure Pregnancy – BetaHCG can mimic LH so tests may show elevated LH Note: A medical drug for inhibiting luteinizing hormone secretion is butinazocine.
Mequinol, MeHQ or 4-methoxyphenol, is an organic compound with the formula CH3OC6H4OH. It is a phenol with a methoxy group in the para position. A colorless solid, it is used in dermatology and organic chemistry.
The earliest fossil echinoderms date to the Cambrian, with the first asterozoans (a group that includes starfish and brittle stars) being the Somasteroidea, which exhibit traits of both groups. Starfish are infrequently found as fossils, possibly because their hard skeletal components separate as the animal decays. Despite this, there are a few places where accumulations of complete skeletal structures occur, fossilized in place in Lagerstätten – so-called "starfish beds". By the late Paleozoic, the crinoids and blastoids were the predominant echinoderms, fragments of which are almost the only fossil found in some limestones. In the two major extinction events that occurred during the late Devonian and late Permian, the blastoids were wiped out and only a few species of crinoids survived. Many starfish species also became extinct in these events, but afterwards the surviving few species quickly diversified rapidly over sixty million years between the beginning and middle of the Middle Jurassic. A 2012 study found that speciation in starfish can occur rapidly. During the last 6,000 years, divergence in the larval development of Cryptasterina hystera and Cryptasterina pentagona has taken place, the former adopting internal fertilization and brooding and the latter remaining a broadcast spawner.
Sources: en.wikipedia.org
== Experiments with argiotoxins == Argiotoxins studies have been particularly made to discover the relation between inhibition, receptors, and ionic channels. Researchers have specifically pursued the blocking of receptors on invertebrates, rather than on vertebrates. Referring to invertebrates, Planorbarius corneus is a mollusc involved in one of the many ionic experiments. To begin with, neurons of molluscan pedal ganglia were isolated and transferred to a special chamber with saline solution and regulated temperature. Then, the observation was based on routine voltage clamp technique. Electrical measurements were obtained from the evaluation of neurons response to various substances (argiopines). In addition to that, crayfish, a freshwater crustacean, has followed a similar protocol to this study. In this case, the analysis was made of the stomach muscles and using the patch clamp technique. The research findings were obtained taking into account the bursts of openings of excitatory channels. Other experiments use spectroscopy in order to analyse and differentiate these molecules. HPLC, mass spectrometry, UV data and amino acid analysis are the elements that allow identifying diverse argiotoxins due to their spectrum. Argiope lobata toxins (Arg 636, Arg 630, Arg 658, Arg 744, Arg 759, Arg 373, Arg 728, Arg 723, ...) show a close similarity in their structures; the subtle differences between them are chemical points, such as N-methyl groups, molecular masses or lysine residues that are determined in a certain position in their structure.
Inverse gas chromatography is a physical characterization analytical technique that is used in the analysis of the surfaces of solids. Inverse gas chromatography or IGC is a highly sensitive and versatile gas phase technique developed over 40 years ago to study the surface and bulk properties of particulate and fibrous materials. In IGC the roles of the stationary (solid) and mobile (gas or vapor) phases are inverted from traditional analytical gas chromatography (GC); IGC is considered a materials characterization technique (of the solid) rather than an analytical technique (of a gas mixture). In GC, a standard column is used to separate and characterize a mixture of several gases or vapors. In IGC, a single standard gas or vapor (probe molecule) is injected into a column packed with the solid sample under investigation. During an IGC experiment a pulse or constant concentration of a known gas or vapor (probe molecule) is injected down the column at a fixed carrier gas flow rate. The retention time of the probe molecule is then measured by traditional GC detectors (i.e. flame ionization detector or thermal conductivity detector). Measuring how the retention time changes as a function of probe molecule chemistry, probe molecule size, probe molecule concentration, column temperature, or carrier gas flow rate can elucidate a wide range of physico-chemical properties of the solid under investigation. Several in depth reviews of IGC have been published previously.
=== Absorbability === Aspect ratio affects the ability of the nanocapsule to penetrate tumor cells. Low aspect ratios (spherical capsules) tend to penetrate cells more easily than high aspect ratios (rod-shaped capsules).
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.